A systematic review of metabolite biomarkers of schizophrenia

Davison, J. C.; O’Gorman, Aoife; Brennan, Lorraine; Cotter, David

doi:10.1016/j.schres.2017.09.021

Cited by 117 publications

(88 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A previous study reported serotonin/tryptophan *1000, antisocial behaviour and global assessment of functioning were good predictors of aggressive behaviours among inmate (AUC = 0.851) [38]. Metabolic predictors always showed variability in different studies with schizophrenia patients [32,73,74]; however, some consistent potential biomarkers of schizophrenia have been discovered [37]. Consequently, more metabolomics studies should be conducted to discover metabolic biomarkers of violent behaviours in schizophrenia.…”

Section: Discussionmentioning

confidence: 97%

“…To find diagnostic biomarkers of schizophrenia, the metabolomics studies were conducted in different samples, such as peripheral blood mononuclear cells [31], serum [32], plasma [33] and urine [34]. Furthermore, the signatures reported by metabolomics studies are in agreement with the polyunsaturated fatty acid metabolism hypothesis [35] and the membrane phospholipid hypothesis [36] of schizophrenia [37]. A study has validated the potential of tryptophan to be a biomarker for aggression [38].…”

Section: Introductionmentioning

confidence: 84%

See 1 more Smart Citation

Dysregulation of amino acids and lipids metabolism in schizophrenia with violence

Chen

Tang³

et al. 2020

BMC Psychiatry

View full text Add to dashboard Cite

Background: Many studies have related biochemical characteristics to violence and have reported schizophrenia could elevated the risk of violent behaviour. However, the metabolic characteristics of schizophrenia patients with violence (V.SC) are unclear. Methods: To explore the metabolic characteristics of schizophrenia with violence and to identify potential biomarkers, untargeted metabolomics was performed by using gas chromatography time-of-flight mass spectrometry to analyse the plasma metabolites of fifty-three V.SC and twenty-four schizophrenia patients without violence (NV.SC). Multivariate and univariate analyses were performed to identify differential metabolites and biomarkers. Violence was assessed by the MacArthur Violence Assessment Study method. Psychiatric symptoms were assessed by the Positive and Negative Syndrome Scale. Results: Multivariate analysis was unable to distinguish V.SC from NV.SC. Glycerolipid metabolism and phenylalanine, tyrosine and tryptophan biosynthesis were the differential metabolic pathways between V.SC and NV.SC. We confirmed ten metabolites and five metabolites as metabolic biomarkers of V.SC by random forest and support vector machine analysis, respectively. The biomarker panel, including the ratio of L-asparagine to L-aspartic acid, vanillylmandelic acid and glutaric acid, yielded an area under the receiver operating characteristic curve of 0.808. Conclusions: This study gives a holistic view of the metabolic phenotype of schizophrenia with violence which is characterized by the dysregulation of lipids and amino acids. These results might provide information for the aetiological understanding and management of violence in schizophrenia; however, this is a preliminary metabolomics study about schizophrenia with violence, which needs to be repeated in future studies.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 84%

Dysregulation of amino acids and lipids metabolism in schizophrenia with violence

Chen

Tang³

et al. 2020

BMC Psychiatry

View full text Add to dashboard Cite

show abstract

“…In spite of numerous attempts to provide reliable diagnostic tools of SZ, it remains defined by the identification of behavioral disorders, in particular psychotic symptoms. Several putative biological markers associated with this disorder have been identified [8], including metabolic biomarkers, neurocognitive dysfunction, brain dysmorphology, and neurochemical abnormalities. However, none of these markers have the appropriate sensitivity and specificity in diagnostic tests.…”

Section: Introductionmentioning

confidence: 99%

In Vitro and In Vivo Models for the Investigation of Potential Drugs Against Schizophrenia

et al. 2020

View full text Add to dashboard Cite

Schizophrenia (SZ) is a complex psychiatric disorder characterized by positive, negative, and cognitive symptoms, and is not satisfactorily treated by current antipsychotics. Progress in understanding the basic pathomechanism of the disease has been hampered by the lack of appropriate models. In order to develop modern drugs against SZ, efficient methods to study them in in vitro and in vivo models of this disease are required. In this review a short presentation of current hypotheses and concepts of SZ is followed by a description of current progress in the field of SZ experimental models. A critical discussion of advantages and limitations of in vitro models and pharmacological, genetic, and neurodevelopmental in vivo models for positive, negative, and cognitive symptoms of the disease is provided. In particular, this review concerns the important issue of how cellular and animal systems can help to meet the challenges of modeling the disease, which fully manifests only in humans, as experimental studies of SZ in humans are limited. Next, it is emphasized that novel clinical candidates should be evaluated in animal models for treatment-resistant SZ. In conclusion, the plurality of available in vitro and in vivo models is a consequence of the complex nature of SZ, and there are extensive possibilities for their integration. Future development of more efficient antipsychotics reflecting the pleiotropy of symptoms in SZ requires the incorporation of various models into one uniting model of the multifactorial disorder and use of this model for the evaluation of new drugs.

show abstract

“…Metabolic alterations are widely described in the literature with respect to the psychosis-spectrum conditions. 1 Both risk and clinical manifestations of psychosis are often associated with disturbances in the levels of various cardiometabolic parameters. 2,3 This phenomenon is mostly attributed to environmental factors such as pharmacotherapy with antipsychotics or unhealthy lifestyle among patients.…”

Section: Introductionmentioning

confidence: 99%

<p>Metabolic Parameters in Patients with Prader-Willi Syndrome and DiGeorge Syndrome with Respect to Psychopathological Manifestation</p>

Krefft

Frydecka

Śmigiel

et al. 2020

NDT

View full text Add to dashboard Cite

Purpose: The purpose of our study was to compare the metabolic parameters in two genetic syndromes with a proven high risk of developing psychiatric comorbidities. These comorbidities, especially mood and psychotic disorders, may be associated with a risk of obesity, type 2 diabetes and other components of metabolic syndrome regardless of antipsychotic treatment. Patients and Methods: Two groups of children diagnosed with Prader -Willi syndrome (PWS) (n = 20) and DiGeorge syndrome (DGS) (n = 18), aged 7-18 years, were enrolled. Behavioral symptoms and co-occurring psychopathological symptoms were assessed using the Child Behavior Checklist (CBCL). The levels of following biochemical parameters were measured: glucose, insulin, high-sensitivity C-reactive protein, total cholesterol, low-and high-density lipoproteins (LDL and HDL), triglycerides and non-HDL cholesterol. Additionally, the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) was calculated. Results: There were significantly higher levels of insulin and non-HDL in patients with PWS compared to those with DGS. The scores of four CBCL subscales (social problems, thought problems, delinquent behavior and aggressive behavior) were significantly higher in PWS patients. Higher scores of the CBCL-thought problems were associated with significantly higher levels of insulin as well as HOMA-IR. Conclusion: Patients with PWS seem to be more prone to develop subclinical metabolic dysregulation, in terms of elevated non-HDL levels and insulin levels, compared to DGS patients. Altered insulin sensitivity, present in both groups, even though it is not a specific risk factor, might be related to thought problems associated with psychosis.

show abstract

A systematic review of metabolite biomarkers of schizophrenia

Cited by 117 publications

References 128 publications

Dysregulation of amino acids and lipids metabolism in schizophrenia with violence

Dysregulation of amino acids and lipids metabolism in schizophrenia with violence

In Vitro and In Vivo Models for the Investigation of Potential Drugs Against Schizophrenia

<p>Metabolic Parameters in Patients with Prader-Willi Syndrome and DiGeorge Syndrome with Respect to Psychopathological Manifestation</p>

Contact Info

Product

Resources

About